



## NextCure Announces Pricing of Initial Public Offering of Common Stock

May 9, 2019

BELTSVILLE, Md., May 08, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of \$15.00 per share. NextCure also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock. NextCure's common stock has been approved for listing and is expected to begin trading on The Nasdaq Global Select Market on May 9, 2019 under the ticker symbol "NXTC". Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, will be \$75.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about May 13, 2019, subject to the satisfaction of customary closing conditions.



Morgan Stanley, BofA Merrill Lynch and Piper Jaffray & Co. are acting as joint book-running managers for the offering.

A registration statement relating to the shares being sold in the offering was declared effective by the Securities and Exchange Commission (SEC) on May 8, 2019. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained by visiting EDGAR on the SEC's website at [www.sec.gov](http://www.sec.gov) or from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina 28255-0001, Attn: Prospectus Department, or by email at [dq.prospectus\\_requests@baml.com](mailto:dq.prospectus_requests@baml.com); or Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at [prospectus@pjc.com](mailto:prospectus@pjc.com).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

### **About NextCure, Inc.**

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

Investor Inquiries  
Timothy Mayer, Ph.D.  
NextCure, Inc.  
SVP, Corporate Development  
(240) 762-6486  
[IR@nextcure.com](mailto:IR@nextcure.com)

Media Inquiries  
Shai Biran, Ph.D.  
MacDougall  
(781) 235-3060  
[sbiran@macbiocom.com](mailto:sbiran@macbiocom.com)